Repigmentation achieved from an experimental combination treatment using narrowband UVB (NB-UVB) with afamelanotide, a linear peptide that can activate production of melanin in the skin, is reported to be more stable and extensive than that achieved by NB-UVB alone. Results from a five-month follow-up study of this new combination therapy were recently reported by Clinuvel […]
Company Announcement Friday 21st October 2011 Melbourne, Australia First positive observations from Clinuvel’s US vitiligo trial Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that early clinical observations from the company’s open label Phase II pilot trial (CUV102) of the novel drug SCENESSE® (afamelanotide) in patients with nonsegmental vitiligo (NSV) were presented […]
Nathalie speaks with Madelaine Haddican, MD., about the new clinical trials for Clinuvel’s new treatment for vitiligo. Dr. Haddican will describe the study and give qualification details for those wishing to participate in the trial.
Clinuvel Pharmaceuticals Limited today announced that the US Food and Drug Administration (FDA) has allowed the company to proceed under its current Investigational New Drug to conduct a pilot Phase II clinical trial of its drug afamelanotide (known as SCENESSE®) in patients diagnosed with nonsegmental vitiligo.
Recently I’ve had the great pleasure of speaking with Lachlan Hay, Head of Global Network and Communications, Media Communications & IT Team @ Clinuvel. I had many questions about Scenesse®; how it works, the clinical trial process, and when it will be offered world-wide. Mr. Hay was kind enough to answer every question in detail. […]
Last week I spoke at length with Head of Global Network and Communications at Clinuvel, and by the end of our conversation, I felt like this is a company truly
The previous post about the Scenesse treatment has sparked a lot of interest and many questions about the process. I was contacted by phone this week by a Director from Clinuvel. We had a wonderful conversation; most impressive was
A drug initially developed to protect skin from light and UV will soon be tested as a repigmentation therapy in vitiligo